STOCK TITAN
  1. Home
  2. News
  3. OCGN

Ocugen Inc - OCGN STOCK NEWS

Welcome to our dedicated news page for Ocugen (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ocugen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ocugen's position in the market.

News
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
Rhea-AI Summary
Ocugen, Inc. will showcase its innovative modifier gene therapy platform at the ARVO 2024 Annual Meeting. The platform includes OCU400, OCU410, and OCU410ST for treating retinitis pigmentosa, geographic atrophy, and Stargardt disease, respectively. The company aims to revolutionize the treatment of blindness diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
Rhea-AI Summary
Ocugen, Inc. completes dosing in the second cohort of the Phase 1/2 ArMaDa clinical trial for OCU410, a gene therapy for geographic atrophy in dry age-related macular degeneration. The therapy targets approximately 1 million affected individuals in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
Rhea-AI Summary
Ocugen, Inc. announced that Dr. Shankar Musunuri will participate in a fireside chat at the Emerging Growth Virtual Healthcare Equity Conference. The chat will focus on the Company's recent business and clinical development progress, including FDA clearance for a Phase 3 clinical trial for OCU400, a gene therapy for retinitis pigmentosa.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences
News
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Rhea-AI Summary
Ocugen, Inc. announces positive EMA opinion on OCU400 Phase 3 clinical trial for retinitis pigmentosa, aligning with FDA clearance. EMA's review supports the trial's design and statistical analysis, paving the way for Marketing Authorization Application submission. OCU400, a gene therapy, targets RP patients with RHO gene mutations and gene agnostic mutations. The positive opinion from EMA streamlines the approval process, potentially reducing time and costs for EU marketing authorization, with OCU400 on track for BLA and MAA approvals by 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
none
-
News
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
Rhea-AI Summary
Ocugen, Inc. announces FDA clearance for Phase 3 clinical trial of OCU400 gene therapy for retinitis pigmentosa, a significant milestone in the treatment of RP patients. The trial includes 150 participants with a gene-agnostic approach and aims to address unmet medical needs in RP treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
clinical trial
-
News
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
Rhea-AI Summary
Ocugen, Inc. receives DSMB approval to proceed with medium dose cohort dosing in the Phase 1/2 ArMaDa clinical trial for OCU410, establishing low dose as safe and tolerable. No serious adverse events reported, marking a significant milestone in the clinical development of OCU410.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.19%
Tags
clinical trial
News
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
Rhea-AI Summary
Ocugen, Inc. announces alignment with FDA for broad retinitis pigmentosa indication in Phase 3 clinical trial of OCU400 gene therapy program. The company also received RMAT designation for OCU400. Ocugen provided a general business update for 2023 and highlighted progress on modifier gene therapy programs for blindness diseases. The Phase 1/2 study results for RP patients were recognized by the FDA. OCU410 and OCU410ST gene therapy programs for GA and Stargardt disease are enrolling patients. Ocugen's mucosal vaccine candidate, OCU500, was chosen for NIAID Project NextGen initiative. The Company's regenerative cell therapy platform, NeoCart, is on track for a Phase 3 trial. Financially, Ocugen plans to restate its financial statements for 2022 and 2023 but expects no impact on cash position or projections. Cash, cash equivalents, and investments totaled $39.5 million as of December 31, 2023. The company had 256.6 million shares of common stock outstanding as of that date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.39%
Tags
none
-
News
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
Rhea-AI Summary
Ocugen, Inc. announces that the Data Safety and Monitoring Board (DSMB) has approved proceeding with the medium dose of OCU410ST in the OCU410ST clinical trial for Stargardt disease. The favorable safety and tolerability profile of OCU410ST allows for evaluation of higher doses, addressing the unmet medical need for Stargardt patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.39%
Tags
none
-
News
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
Rhea-AI Summary
Ocugen, a biotechnology company, will host a conference call to provide a business update with financials for 2023. The call will take place on April 2, 2024, at 8:30 a.m. ET. Dial-in numbers and webcast details are provided for participation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.39%
Tags
conferences
News
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
Rhea-AI Summary
Ocugen, Inc. appoints Dr. Huma Qamar as Chief Medical Officer (CMO) to lead clinical development. Dr. Qamar's rich background in clinical research and expertise in various therapeutic areas positions Ocugen well for future success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.63%
Tags
management
Stock OCGN logo
Ocugen Inc

Nasdaq:OCGN

OCGN Rankings

#3335 Ranked by Market Cap
#5296 Ranked by Stock Gains
N/A Ranked by Dividends

OCGN Stock Data

438.79M
252.38M
1.45%
10.33%
16.95%
Sanitary Paper Product Manufacturing
Manufacturing
Link
US
Malvern

About OCGN

ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.